DAX23.970 -1,0%ESt505.338 -0,3%Top 10 Crypto16,23 +2,0%Dow44.838 -0,1%Nas21.179 +0,3%Bitcoin101.764 +0,1%Euro1,1587 ±-0,0%Öl70,22 -0,3%Gold3.311 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Volkswagen (VW) vz. 766403 RENK RENK73 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 Bayer BAY001 Deutsche Bank 514000 BASF BASF11 Tesla A1CX3T DroneShield A2DMAA Porsche PAG911 Novo Nordisk A3EU6F HENSOLDT HAG000 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-EU-Zolldeal im Blick: DAX schließt unter 24.000 Punkten -- US-Börsen letztlich uneins -- NVIDIA-Aktie: Huawei stellt Konkurrenzsystem vor -- Tilray, TUI, Clara Tech, D-Wave, PUMA, Intel im Fokus
Top News
Rekordlaune mit Risiko: Warum Anleger bei Bitcoin jetzt wachsam bleiben sollten Rekordlaune mit Risiko: Warum Anleger bei Bitcoin jetzt wachsam bleiben sollten
Ist passives Investieren mit ETFs wirklich "Investieren für Faule"? Ist passives Investieren mit ETFs wirklich "Investieren für Faule"?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Acurx Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
0,3450 EUR ±0,0000 EUR ±0,00 %
BMN
0,3970 USD -0,0070 USD -1,73 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.10,77 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3CSCG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00510M1045

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolACXP

Acurx Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireAcurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
ZacksAre Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
BenzingaAcurx Pharmaceuticals Shares Are Up Today: What's Going On?
Wer­bungAcurx Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireAcurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
PR NewswireAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for...
PR NewswireAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
PR NewswireAcurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
PR NewswireAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
PR NewswireIndian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
ZacksAcurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
ZacksAcurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
PR NewswireAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
BenzingaWhy Acurx Pharmaceuticals (ACXP) Shares Are Down 30%
PR NewswireAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
PR NewswireAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
PR NewswireAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
PR NewswireAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
PR NewswireAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
PR NewswireAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
PR NewswireAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
PR NewswireAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
PR NewswireAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
PR NewswireJPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
PR NewswireAcurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
PR NewswireAcurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
ZacksHere's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
PR NewswireAcurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
PR NewswireAcurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
PR NewswireAcurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
PR NewswireAcurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
PR NewswireAcurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
PR NewswireAcurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
PR NewswireAcurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
PR NewswireAcurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
PR NewswireAcurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
PR NewswireAcurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
PR NewswireACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireAcurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
PR NewswireUSPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
PR NewswireAcurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals News

Acurx Pharmaceuticals News: auf dieser Seite finden Sie alle Acurx Pharmaceuticals News und Nachrichten zur Acurx Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Acurx Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Acurx Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.